#China #Guangzhou #Simcere #Fermion #SSTR4 Agonist

Collaboration Announcement for Pain Treatment

In a groundbreaking move within the pharmaceutical industry, Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited have officially entered into a collaborative agreement to accelerate the development of FZ002-037, China's first SSTR4 agonist specifically designed for managing pain. This exciting partnership signifies a major advancement in pain therapy and highlights China's growing role in pharmaceutical innovation.

Understanding FZ002-037

FZ002-037 is an oral small-molecule SSTR4 agonist developed with high selectivity, ensuring effective treatment options for patients without the common central nervous system side effects associated with other pain-relief medications. Historically, pain management has been a challenging area of medicine, often hindered by issues related to addiction and side effects from opioids. However, preclinical studies indicate that FZ002-037 provides significant peripheral analgesia, making it an appealing alternative for individuals in need of long-term pain relief.

This drug is not only the first of its kind developed domestically in China; it is also the second SSTR4 agonist in the world to reach clinical-stage trials. Its journey into clinical evaluation has already seen successful completion of Phase I trials, and preparations for Phase II studies focusing on diabetic peripheral neuropathy are underway.

Leadership Voices

Dr. Deco Deng, the Founder of Fermion, expressed enthusiasm regarding the strategic partnership with Simcere, emphasizing the innovative potential of FZ002-037. He remarked, "We are delighted to partner with Simcere, a leading pharmaceutical company. With this collaboration, we hope to significantly enhance the treatment landscape for patients suffering from pain."

On the other hand, Zhou Gaobo, Chief Investment Officer of Simcere, spoke about the unmet medical need related to pain management. He stated, "Pain significantly affects patients' quality of life and remains a major unmet clinical need. Our core mission is to address these 'clinical pain points'. We are optimistic about our collaboration with Fermion, paving the way for safer and more effective pain therapies."

The Collaboration Details

Under this exclusive agreement, Simcere secures the rights to develop and commercialize FZ002-037 across Greater China, including Mainland China, Hong Kong, Macau, and Taiwan. As part of the collaboration framework, Fermion will receive an upfront payment and subsequent milestone payments based on the development phases, alongside tiered royalties from future sales.

About the Companies

Fermion Technology

Founded in 2019, Fermion is an AI-driven biotechnology company dedicated to developing best-in-class products in neurology and autoimmune fields. By leveraging its sophisticated Drug Studio AI platform, Fermion aims to prioritize high target selectivity and tissue targeting to enhance drug safety and efficacy.

Simcere Pharmaceutical

Simcere, publicly traded under HKEX: 2096, is renowned for its commitment to driving innovative drug development. With a focus on oncology, central nervous system disorders, and autoimmune diseases, Simcere houses a state-of-the-art research laboratory and actively collaborates with numerous global biopharmaceutical companies and medical institutes.

The Future of Pain Management

FZ002-037 is positioned to revolutionize how chronic and acute pain conditions are treated, emphasizing efficacy without the addiction risks posed by opioids. As the development continues, this partnership not only signifies a monumental step for Fermion and Simcere but also inspires hope for patients seeking effective pain management solutions, heralding a new era in pharmaceutical innovation in China.

For further details about this strategic partnership and FZ002-037, visit Fermion's website at www.fulmz.com or Simcere's at www.simcere.com.